These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 36597128)

  • 1. Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial.
    Hutchings M; Morschhauser F; Iacoboni G; Carlo-Stella C; Offner FC; Sureda A; Salles G; Martínez-Lopez J; Crump M; Thomas DN; Morcos PN; Ferlini C; Bröske AE; Belousov A; Bacac M; Dimier N; Carlile DJ; Lundberg L; Perez-Callejo D; Umaña P; Moore T; Weisser M; Dickinson MJ
    J Clin Oncol; 2021 Jun; 39(18):1959-1970. PubMed ID: 33739857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. T and NK cells of B cell NHL patients exert cytotoxicity against lymphoma cells following binding of bispecific tetravalent antibody CD19 × CD3 or CD19 × CD16.
    Pörtner LM; Schönberg K; Hejazi M; Brünnert D; Neumann F; Galonska L; Reusch U; Little M; Haas R; Uhrberg M
    Cancer Immunol Immunother; 2012 Oct; 61(10):1869-75. PubMed ID: 22976535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mosunetuzumab Safety Profile in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma: Clinical Management Experience From a Pivotal Phase I/II Trial.
    Matasar M; Bartlett NL; Shadman M; Budde LE; Flinn I; Gregory GP; Kim WS; Hess G; El-Sharkawi D; Diefenbach CS; Huang H; To I; Parreira J; Wu M; Kwan A; Assouline S
    Clin Lymphoma Myeloma Leuk; 2024 Apr; 24(4):240-253. PubMed ID: 38195322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular assessment of intratumoral immune cell subsets and potential mechanisms of resistance to odronextamab, a CD20×CD3 bispecific antibody, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
    Brouwer-Visser J; Fiaschi N; Deering RP; Cygan KJ; Scott D; Jeong S; Boucher L; Gupta NT; Gupta S; Adler C; Topp MS; Bannerji R; Duell J; Advani RH; Flink DM; Chaudhry A; Thurston G; Ambati SR; Jankovic V
    J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38519055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pharmacological characteristics and clinical outcomes of Epcoritamab (recombinant) (Epkinly
    Takaura K; Ando H; Ganoza ER
    Nihon Yakurigaku Zasshi; 2024; 159(1):61-68. PubMed ID: 38171842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of anti-CD79b/CD3 bispecific antibody, a potential therapy for B cell malignancies.
    Wang J; Li C; He K; Kuang Z; Lu J; Yao Y; He F; Li N; Li L; Fu F; Wu Z; Zhou S; Kang D; Qiu X; Wu M; Liu Y; Cao X; Xu M; Chen B; Wu W; Guo F
    Cancer Immunol Immunother; 2023 Feb; 72(2):493-507. PubMed ID: 35963895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First-in-human study of JNJ-67571244, a CD33 × CD3 bispecific antibody, in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome.
    Narayan R; Piérola AA; Donnellan WB; Yordi AM; Abdul-Hay M; Platzbecker U; Subklewe M; Kadia TM; Alonso-Domínguez JM; McCloskey J; Bradford K; Curtis M; Daskalakis N; Guttke C; Safer K; Hiebert B; Murphy J; Li X; Duchin K; Esteban D
    Clin Transl Sci; 2024 Mar; 17(3):e13742. PubMed ID: 38494922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CLN-978, a novel half-life extended CD19/CD3/HSA-specific T cell-engaging antibody construct with potent activity against B-cell malignancies with low CD19 expression.
    Meetze K; Mehta NK; Li B; Michaelson JS; Baeuerle PA
    J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37586770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and tolerability of AMG 330 in adults with relapsed/refractory AML: a phase 1a dose-escalation study.
    Ravandi F; Subklewe M; Walter RB; Vachhani P; Ossenkoppele G; Buecklein V; Döhner H; Jongen-Lavrencic M; Baldus CD; Fransecky L; Pardee TS; Kantarjian H; Yen PK; Mukundan L; Panwar B; Yago MR; Agarwal S; Khaldoyanidi SK; Stein A
    Leuk Lymphoma; 2024 May; ():1-11. PubMed ID: 38712673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First-in-human clinical trial results with ABBV-184, a first-in-class T-cell receptor/anti-CD3 bispecific protein, in adults with previously treated AML or NSCLC.
    Peterlin P; Saada-Bouzid E; Moskovitz M; Pigneux A; Yuda J; Sinnollareddy M; Henner WR; Chen D; Freise KJ; Leibman RS; Avigdor A; Shimizu T
    Expert Rev Anticancer Ther; 2024 Jul; ():1-12. PubMed ID: 38946484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of Extended Pirtobrutinib Exposure in Relapsed and/or Refractory B-Cell Malignancies.
    Roeker LE; Coombs CC; Shah NN; Jurczak W; Woyach JA; Cheah CY; Patel K; Maddocks K; Wang Y; Zinzani PL; Munir T; Koh Y; Thompson MC; Muehlenbein CE; Wang C; Sizelove R; Abhyankar S; Hasanabba S; Tsai DE; Eyre TA; Wang M
    Acta Haematol; 2024 Jun; ():1-17. PubMed ID: 38824917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sinonasal Lymphoma Presenting as a Probable Sanctuary Site for Relapsed B Acute Lymphoblastic Leukaemia: A Case Report and Review of the Literature.
    Lim WY; Care R; Lau M; Chiruka S; Dawes PJ
    Case Rep Hematol; 2015; 2015():697957. PubMed ID: 26697242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bispecific and multispecific antibodies in oncology: opportunities and challenges.
    Goebeler ME; Stuhler G; Bargou R
    Nat Rev Clin Oncol; 2024 Jul; 21(7):539-560. PubMed ID: 38822215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T-Cell Engagers-The Structure and Functional Principle and Application in Hematological Malignancies.
    Cech P; Skórka K; Dziki L; Giannopoulos K
    Cancers (Basel); 2024 Apr; 16(8):. PubMed ID: 38672662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New immune cell engagers for cancer immunotherapy.
    Fenis A; Demaria O; Gauthier L; Vivier E; Narni-Mancinelli E
    Nat Rev Immunol; 2024 Jul; 24(7):471-486. PubMed ID: 38273127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bispecific Antibodies in Hematological Malignancies: A Scoping Review.
    Omer MH; Shafqat A; Ahmad O; Alkattan K; Yaqinuddin A; Damlaj M
    Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760519
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies.
    Tapia-Galisteo A; Álvarez-Vallina L; Sanz L
    J Hematol Oncol; 2023 Jul; 16(1):83. PubMed ID: 37501154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of AFM11 in the treatment of patients with B-cell malignancies: findings from two phase 1 studies.
    Topp M; Dlugosz-Danecka M; Skotnicki AB; Salogub G; Viardot A; Klein AK; Hess G; Michel CS; Grosicki S; Gural A; Schwarz SE; Pietzko K; Gärtner U; Strassz A; Alland L; Mayer J
    Trials; 2023 Jan; 24(1):4. PubMed ID: 36597128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
    Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
    MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.